Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) is a whole-joint disorder characterized by cartilage degeneration, synovial inflammation, subchondral bone remodeling, pain and progressive functional impairment. Current management remains largely symptomatic, and no widely accepted disease-modifying therapy is available. Extracellular vesicles (EVs) mediate intercellular communication by transferring regulatory RNAs, proteins, lipids, metabolites and other bioactive molecules. Their effects depend on the source and state of the donor cell, cargo composition, recipient phenotype, dose and disease context. EVs released by inflamed or mechanically stressed joint tissues can amplify matrix catabolism, inflammasome activation, senescence, defective autophagy and osteochondral crosstalk. By contrast, selected mesenchymal stromal cell (MSC)-derived, preconditioned, engineered or biomaterial-delivered EV preparations show reparative and immunomodulatory activity in preclinical models. Synovial-fluid and circulating EV profiles are also being investigated as biomarkers, although independent validation remains limited. In this narrative review, we integrate EV-mediated communication across cartilage, synovium, subchondral bone and immune compartments. We also critically assess the evidence for OA biomarkers and cell-free therapies. Current evidence supports EVs as candidate biomarkers and experimental therapeutic platforms, but does not yet establish their clinical diagnostic utility or therapeutic efficacy in OA. Translation requires independent biomarker validation, standardized EV characterization and dosing, mechanism-linked potency assays, and controlled clinical trials that distinguish symptomatic improvement from structural disease modification.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: